![Gordon R. B. Skinner](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Gordon R. B. Skinner
Corporate Officer/Principal at Vaccine Research International Plc
Gordon R. B. Skinner active positions
Companies | Position | Start | End |
---|---|---|---|
Vaccine Research International Plc
![]() Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Corporate Officer/Principal | 09/04/2010 | - |
Career history of Gordon R. B. Skinner
Former positions of Gordon R. B. Skinner
Companies | Position | Start | End |
---|---|---|---|
HIV-VAC, Inc.
![]() HIV-VAC, Inc. Miscellaneous Commercial ServicesCommercial Services HIV-VAC, Inc. develops and markets proposed vaccine designed to combat HIV/AIDS. This proposed vaccine, which is called NFU.Ac.HIV, was developed by Dr. Gordon Skinner, director of research, through the University of Birmingham, in the U.K. The proposed vaccine was licensed to Intracell Vaccines Limited from the University of Birmingham. The company was founded in 1997 and is headquartered in Ontario, CA. | Director/Board Member | 09/04/2010 | 28/10/2010 |
Chief Tech/Sci/R&D Officer | 09/04/2010 | 28/10/2010 | |
GRUPO INTERNATIONAL INC. | Director/Board Member | 01/04/1999 | - |
Chief Tech/Sci/R&D Officer | 01/04/1999 | - | |
Intracell Vaccines Ltd.
![]() Intracell Vaccines Ltd. Medical SpecialtiesHealth Technology Intracell Vaccines Ltd. develops vaccines. The company is headquartered in Gaithersburg, MD. | Director/Board Member | 09/04/2010 | - |
Training of Gordon R. B. Skinner
University of Glasgow | Undergraduate Degree |
University of Birmingham | Doctorate Degree |
Statistics
International
United Kingdom | 4 |
Canada | 3 |
United States | 2 |
Operational
Director/Board Member | 3 |
Chief Tech/Sci/R&D Officer | 2 |
Doctorate Degree | 2 |
Sectoral
Commercial Services | 3 |
Health Technology | 3 |
Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Listed companies | 1 |
---|---|
GRUPO INTERNATIONAL INC. | Health Technology |
Private companies | 3 |
---|---|
HIV-VAC, Inc.
![]() HIV-VAC, Inc. Miscellaneous Commercial ServicesCommercial Services HIV-VAC, Inc. develops and markets proposed vaccine designed to combat HIV/AIDS. This proposed vaccine, which is called NFU.Ac.HIV, was developed by Dr. Gordon Skinner, director of research, through the University of Birmingham, in the U.K. The proposed vaccine was licensed to Intracell Vaccines Limited from the University of Birmingham. The company was founded in 1997 and is headquartered in Ontario, CA. | Commercial Services |
Intracell Vaccines Ltd.
![]() Intracell Vaccines Ltd. Medical SpecialtiesHealth Technology Intracell Vaccines Ltd. develops vaccines. The company is headquartered in Gaithersburg, MD. | Health Technology |
Vaccine Research International Plc
![]() Vaccine Research International Plc Miscellaneous Commercial ServicesCommercial Services Vaccine Research International Plc is a British company that focuses on conducting clinical trials to evaluate the effectiveness of vaccine SA75 in preventing staphylococcal infections in hospital patients and the wider community. | Commercial Services |
- Stock Market
- Insiders
- Gordon R. B. Skinner
- Experience